

# Cardiff & Vale UHB Biologic Pathway for Rheumatoid Arthritis

Failed at least 2 DMARDs (one must be methotrexate) and DAS28>5.1 (NICE TA375)

Patients with Concomitant Interstitial Lung Disease or Bronchiectasis Or High risk of TB or Quantiferon positive<sup>3</sup>

MTX tolerant

MTX + TNF inhibitor or  
MTX + Tocilizumab or  
MTX + Abatacept (NICE TA375) or  
MTX + Rituximab (RF+ and/or ACPA+)<sup>1</sup>

Termination of treatment due to side effect

MTX + Rituximab (NICE TA195)

Hb≤8g/dl, Lymphocyte count ≤0.5 or risk/history of DVT/PE

MTX + Tocilizumab (NICE TA247) or  
MTX + Sarilumab (NICE TA485) or  
MTX + Baricitinib (NICE TA466) or  
MTX + Tofacitinib (NICE TA 480)

MTX + Abatacept

MTX + alternative TNF inhibitor

MTX tolerant

MTX + Abatacept (NICE TA375)

MTX + Rituximab (NICE TA375)

MTX + Tocilizumab (NICE TA375)

RF and ACPA negative<sup>2</sup> or  
Contraindication to Rituximab

MTX + Tocilizumab (TA247) or  
MTX + Sarilumab (NICE TA485)

MTX intolerant Or  
Plan to become pregnant in the near future

Plan to become pregnant in the near future

Certolizumab (NICE TA375)

Hb≤8g/dl, Lymphocyte count ≤0.5 or risk/history of DVT/PE

Etanercept (NICE TA375)<sup>5</sup>

Tocilizumab (NICE TA375)<sup>4</sup> or  
Sarilumab (NICE TA485)

Baricitinib (NICE TA466) or  
Tofacitinib (NICE TA 480) or  
Etanercept (NICE TA375)<sup>5</sup>

Alternative TNF inhibitor (NICE TA375)

## References

- Porter D et al. Lancet. 2016 Jul 16;388(10041):239-47
- Isaacs JD et al. Ann Rheum Dis. 2013 Mar;72(3):329-36
- Cantini F et al. J Rheumatol Suppl.2014;91:56-64.
- Gabay C et al. Lancet. 2013 ;381(9877):1541-50.
- Tarp S et al. Semin Arthritis Rheum 2016 (epub)